EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Challenges in scaling up AAV-based gene therapy manufacturing

Ziyu Jiang, Paul A Dalby

Trends in Biotechnology · 2023-10 · 41 (10) · 1268-1281

DOI: 10.1016/j.tibtech.2023.04.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2023-10. Verfasst von Ziyu Jiang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK. Electronic address: z.jiang.19@ucl.ac.uk. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accelerating the scale up of adeno-associated virus (AAV) manufacture is highly desirable to meet the increased demand for gene therapies. However, the development of bioprocesses for AAV gene therapies remains time-consuming and challenging. The quality by design (QbD) approach ensures bioprocess designs that meet the desired product quality and safety profile. Rapid stress tests, developability screens, and scale-down technologies have the potential to streamline AAV product and manufacturing bioprocess development within the QbD framework. Here we review how their successful use for antibody manufacture development is translating to AAV, but also how this will depend critically on improved analytical methods and adaptation of the tools as more understanding is gained on the critical attributes of AAV required for successful therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusGenetic TherapyCommerceQuality ControlGenetic Vectors

Stichwörter der Autor:innen

adeno-associated virusgene therapymanufacturingquality by designscale down

Autor:innen und Institutionen

  • Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK. Electronic address: z.jiang.19@ucl.ac.uk.
  • Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK. Electronic address: p.dalby@ucl.ac.uk.

Förderung

  • Engineering and Physical Sciences Research Council

Zitieren

APA

Jiang, Z., & Dalby, P. A. (2023). Challenges in scaling up AAV-based gene therapy manufacturing. Trends in Biotechnology, 41(10), 1268-1281. https://doi.org/10.1016/j.tibtech.2023.04.002

Vancouver

Jiang Z, Dalby PA. Challenges in scaling up AAV-based gene therapy manufacturing. Trends in Biotechnology. 2023;41(10):1268-1281. doi:10.1016/j.tibtech.2023.04.002

BibTeX
@article{Jiang2023,
  author = {Jiang, Ziyu and Dalby, Paul A},
  title = {Challenges in scaling up AAV-based gene therapy manufacturing},
  journal = {Trends in Biotechnology},
  year = {2023},
  volume = {41},
  number = {10},
  pages = {1268--1281},
  doi = {10.1016/j.tibtech.2023.04.002}
}
Kostenlos starten →